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The Journal of Immunology
Skin Metabolites Define a New Paradigm in the Localization
of Skin Tropic Memory T Cells
Michelle L. McCully,* Paul J. Collins,* Timothy R. Hughes,* Christopher P. Thomas,*
Jaak Billen,† Valerie B. O’Donnell,* and Bernhard Moser*
The localization of memory T cells to human skin is essential for long-term immune surveillance and the maintenance of barrier
integrity. The expression of CCR8 during naive T cell activation is controlled by skin-specific factors derived from epidermal ker-
atinocytes and not by resident dendritic cells. In this study, we show that the CCR8-inducing factors are heat stable and protease
resistant and include the vitamin D3 metabolite 1a,25-dihydroxyvitamin D3 and PGE2. The effect of either metabolite alone on
CCR8 expression was weak, whereas their combination resulted in robust CCR8 expression. Elevation of intracellular cAMP was
essential because PGE2 could be substituted with the adenylyl cyclase agonist forskolin, and CCR8 expression was sensitive to
protein kinase A inhibition. For effective induction, exposure of naive T cells to these epidermal factors needed to occur either
prior to or during T cell activation even though CCR8 was only detected 4–5 d later in proliferating T cells. The importance of
tissue environments in maintaining cellular immune surveillance networks within distinct healthy tissues provides a paradigm
shift in adaptive immunity. Epidermal-derived vitamin D3 metabolites and PGs provide an essential cue for the localization of
CCR8+ immune surveillance T cells within healthy human skin. The Journal of Immunology, 2015, 195: 96–104.
T
he localization of memory T cells to distinct, nonover-
lapping peripheral tissues requires the coordinated ex-
pression of specific adhesion molecules and chemokine
receptors (1, 2). However, the mechanisms underlying the induc-
tion of these specific tissue-homing programs are only beginning
to be elucidated. Once these mechanisms are identified, the ex-
pression of such factors can be targeted to either promote (vac-
cination) or dampen (autoimmunity) immune responses at specific
tissue sites.
Recent studies have implicated vitamins A and D in the control of
T cell homing to the small intestine and skin tissue, respectively (3,
4). Vitamin A is highly concentrated in the gut (5), and retinoic
acid, an active metabolite of vitamin A, has been shown to play
a crucial role in the induction of the “gut-homing” receptors CCR9
and a4b7 in murine and human T cells (6–8). Conversely, vitamin
D3, which is produced in the skin in response to UV exposure (9),
has been implicated in the regulation of a “skin-homing” mecha-
nism because its active metabolite, 1a,25-dihydroxyvitamin D3
(1,25(OH)2D3), was shown to induce expression of the chemokine
receptor CCR10 in human T cells (10). However, the conditions
required to induce CCR10 expression did not correlate with in-
duction of other skin-homing receptors, including the adhesion
molecule cutaneous lymphocyte–associated Ag, and for naive
T cells, the effect was dependent on the presence of IL-12.
We recently reported that the chemokine receptor CCR8 is
highly expressed by memory T cells localized in healthy human
skin and a small fraction of CLA+ memory T cells in blood (11,
12). Further investigation revealed that the induction of CCR8
expression during in vitro T cell activation depended on the ad-
dition of soluble skin factors that were produced by epidermal
tissue (12). Moreover, cultured keratinocytes but not dermal
fibroblasts or skin-unrelated epithelial cell lines produced CCR8-
inducing factors, emphasizing the skin selectivity of the CCR8
induction process. Because the epidermis-derived factors respon-
sible for the observed CCR8 induction in T cells were not known,
we undertook a detailed investigation into the nature of these
factors and their mode of action during T cell activation. In this
study, we report that the active vitamin D3 metabolite 1,25(OH)2D3
and PGE2 work in concert to induce CCR8 expression in human
T cells and that these factors need to be present at the beginning of
culture during in vitro T cell activation. Murine skin also produces
CCR8-inducing factors, and CCR8-expressing cells are also en-
riched in mouse skin tissue, indicating that the CCR8-controlled
localization of skin-specific memory T cells underlies a con-
served mechanism and emphasizes the importance of the skin
tissue environment in the homeostasis of the local memory T cell
compartment.
Materials and Methods
Media and reagents
Complete RPMI (cRPMI) medium consisted of RPMI 1640 plus 2 mM
L-glutamine, 1% nonessential amino acids, 1% sodium pyruvate, 50 mg/ml
penicillin/streptomycin, 20 mM HEPES, and 10% FBS (Life Technolo-
gies). AB-RPMI consisted of cRPMI supplemented with 10% pooled hu-
man AB serum. Human T-Activator CD3/CD28 Dynabeads and CFSE were
purchased from Life Technologies. Purified anti-mouse CD3 (145-2C11)
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and CD28 (37.51) Abs and recombinant mouse IL-2 were obtained from
BioLegend. Recombinant human IL-12 and IFN-g were purchased from
PeproTech; TNF-a and IL-6 were from Miltenyi Biotech, whereas IFN-a
was purchased from Roche. 1,25(OH)2D3, 25-hydroxyvitamin D3, and PGE2
were purchased from Sigma-Aldrich. Forskolin, 19R-OH-PGE1, CAY10598,
Butaprost, L-161,982, AH6809, and SC19220 were purchased from Cayman
Chemical. The cAMP-dependent protein kinase A (PKA) inhibitor peptide
(PKI)14–22 was obtained from Tocris Bioscience, whereas Raf1 kinase in-
hibitor 1 and wortmannin were from Enzo Life Sciences. 2-Cl-8-MA-cAMP,
N6-MBC-cAMP, and 8-Piperidino-cAMP were purchased from BioLog.
Human cell isolation and culture
All research involving work with human blood and tissue samples were
approved by the local Research Ethics Commission. Informed consent was
obtained from each participating subject before sampling in accordance with
the Declaration of Helsinki. PBMCs were isolated from healthy donors by
density gradient centrifugation using Lymphoprep (Axis-Shield), according
to the local ethical guidelines on experimentation with human samples. T cell
subsets were purified byMACS, according to themanufacturer’s instructions
(Miltenyi Biotec). Purified human T cells were isolated by negative selec-
tion using Pan T Cell Isolation Kit II. Naive T cells were further isolated by
depleting CD45RO+ cells using CD45RO microbeads. Purity was evaluated
by flow cytometry and ranged between 92 and 99%.
Mouse tissue cell isolation
Male and female C57BL/6 Thy1.1+ (B6) mice were bred in-house and used
between 6 and 12 wk of age. All studies complied with institutional
guidelines and the U.K. Home Office for Laboratory Animal Care regu-
lations. Peripheral blood was harvested by cardiac puncture into heparin-
ized tubes and subsequently layered on Lymphoprep to obtain mononuclear
cells. Thymus, lymph nodes, and spleen were harvested and mashed through
a 40-mm nylon cell strainer to prepare single-cell suspensions. Skin tissue
was excised after hair removal, scraped to remove s.c. fat, cut into strips, and
floated with the dermis side down in Dispase II buffer at 37˚C. After 90 min,
the epidermis was separated from dermis, and the epidermal sheets were
floated on cRPMI to generate epidermis-conditioned medium (ECM). Al-
ternatively, the whole skin was chopped and incubated in 13 PBS sup-
plemented with 25 mg/ml Liberase TM and 250 mg/ml DNase I (Roche) at
37˚C shaking for 30 min. Single-cell suspensions were subjected to Lym-
phoprep separation prior to staining for flow cytometry or sorted based on
CD45 expression using CD45 microbeads (Miltenyi Biotec). Purified naive
splenic T cells were isolated by negative selection using the Easysep Mouse
Pan Naive T Cell Isolation Kit (Stemcell Technologies), according to man-
ufacturer’s instructions.
Epidermis-conditioned medium
Freshly isolated epidermal sheets were cultured on AB-RPMI for 3 d. After
3 d, supernatants were harvested, centrifuged, 0.22 mM filtered and either
used directly or stored frozen until use. Keratinocyte-conditioned medium
(KCM) was generated as described previously (12). To inactivate proteins,
conditioned medium was subsequently heated (80˚C) or heated and
digested with either 0.2–10 U/ml trypsin-agarose beads or proteinase
K–Eupergit beads (20 U/ml) for 6 h at 37˚C (Sigma-Aldrich). Effectiveness
of digestion was determined based on loss of HRP enzymatic activity in
spiked medium. For the preparation of mouse skin conditioned medium,
ears were split into dorsal and ventral halves and floated dermis side down
on cRPMI for 3 d at 37˚C. For ECM, dorsal epidermal sheets were pre-
pared and incubated as described previously. Cell-free supernatant was
then collected, filtered through a 0.22-mm filter, and stored until use.
T cell stimulations
Naive T cells (1 3 105 cells/well) were stimulated with anti-CD3/CD28
Dynabeads at a ratio of 4:1 in cRPMI in the presence of various additives
for 5 d. For prostaglandin E (EP) receptor inhibition or signaling inhibitor
assays, cells were preincubated with inhibitors for 30 min prior to the
addition of ECM or PGE2 and left overnight. The following day, cells were
washed and stimulated with anti-CD3/CD28 Dynabeads at a ratio of 4:1
in cRPMI. For priming experiments, cells were incubated with 100 nM
25(OH)D3 or 1,25(OH)2D3 with or without IL-12 (12.5 ng/ml) overnight
and then washed and stimulated with anti-CD3/CD28 Dynabeads in the
presence of PGE2 or EP receptor agonists.
Murine naive T cells were stimulated with plate-bound anti-CD3 (1 mg/
ml) plus soluble anti-CD28 (1 mg/ml) and 30 U/ml recombinant mouse
IL-2 in cRPMI supplemented with 50 mM 2-ME for 5 d either alone or in
the presence of conditioned medium generated from whole ear skin or
epidermal sheets from dorsal skin.
Flow cytometry
Cells were acquired using a FACSCanto II (BD Biosciences) and analyzed
with FlowJo software (Tree Star). The following anti-human mAbs were
used: anti-CD3 (UCHT1), anti-CD4 (SK3), anti-CD8 (SK1), anti-CD45RA
(HI100), anti-CD45RO (UCHL1), and anti-CCR7 (3D12) from BD Bio-
sciences; and anti-CXCR3 (49801) and anti-CCR10 (314305) from R&D
Systems. The following anti-mouse mAbs were used: anti-CD3 (145-2C11),
anti-CD4 (RM4-4), anti-CD8 (53-6.7), anti-CD11b (M1/70), anti-CD11c
(HL3), anti-CD27 (LG.3A10), anti-CD44 (IM7), anti-CD45 (30-F11), and
anti-CD62L (MEL-14). Human CCR8 expression was detected as reported
previously (12). Mouse CCR8 expression was detected using a custom-
made AF647-labeled murine CCL1 (AF647-muCCL1; Almac). Appro-
priate isotype controls were included in all cases. Live cells were gated
based on their light scatter properties, the exclusion of doublets on for-
ward scatter area/height plots, and the “dumping” of dead cells using
Aqua Live/Dead staining (Life Technologies).
RNA isolation and quantitative PCR
Total RNA was extracted with TRIzol reagent (Invitrogen Life Technolo-
gies), according to the manufacturer’s instructions. Genomic DNA was
removed by treatment with recombinant DNase I (Ambion Life Technol-
ogies), and RNA quality and quantity were determined with a nanodrop
spectrophotometer. cDNA was synthesized from 200 ng RNA using the
High Capacity RNA-to-cDNA kit from Applied Biosystems. For quanti-
tative RT-PCR, the CCR8 mRNA level was determined using TaqMan
Gene Expression assays and TaqMan Universal Master Mix II (Applied
Biosystems), according to the manufacturer’s instructions. Reactions were
performed using a ViiA7 real-time PCR system (Life Technologies) and
were run in triplicate. Water (no template control) and mRNA without
reverse transcriptase were used as negative controls. Relative quantification
of CCR8 mRNA levels was performed using the comparative Ct method
with b-actin as the reference gene and the equation 22DDCt.
Intracellular cAMP detection
Intracellular cAMP levels were determined using the cAMP Biotrak EIA kit
(GE Life Sciences). Briefly, naive T cell were incubated for 30 min in either
media alone or media plus 15% ECM, then washed, and lysed using the
supplied buffer. The amount of intracellular cAMP present in each sample
was determined based on the standard curve and calculated as the fold
increase in ECM-treated cultures over media alone.
PGE2 level determination by mass spectrometry
For ECM lipid extraction, a modified Bligh and Dyer extraction was
performed. An internal standard of PGE2-d4 (10 ng) was added to account
for variances in sample extraction. A 1-ml sample of ECM was added to
3.75 ml chloroform:methanol (1:2) in a glass extraction vial (13). The
mixture was vortexed thoroughly for 1 min before the addition of 1.25 ml
chloroform and vortexing for an additional minute. HPLC-grade water
(1.25 ml) was added, and the solution was vortexed thoroughly for 1 min.
The sample was centrifuged at 500 3 g for 5 min at 20–22˚C before the
lower layer was carefully removed with a glass Pasteur pipette and
transferred to a clean, labeled glass vial. The samples were dried using
a RapidVap or Dryblock with a nitrogen stream at a temperature of 30˚C.
Lipids were then analyzed using a C18 Spherisorb ODS2, 5mm, 1503 4.6-
mm column (Waters, Hertfordshire, U.K.). The mobile phase was composed
of 0.1% formic acid in water (solvent A) and 0.1% formic acid in acetonitrile
(solvent B), with flow rate 1 ml.min-1. Solvent B was increased from 20 to
42.5% over 50 min, then increased to 90% over 10.5 min, held for 4 min, and
then returned to 20% over 1 min. Equilibration time between runs was 14 min.
Mass spectroscopy was performed using an ABSciex 4000 Q-Trap, using
DP-55V, CE-26V monitoring the parent to daughter m/z of 351–271 (14).
Statistics
Significance testing was performed using the Mann–Whitney U test,
Dunn’s Multiple Comparison Test, one-way or two-way ANOVA with
Dunnett posttest in GraphPad Prism (GraphPad Software). A difference
between groups was considered significant when p , 0.05.
Results
Imprinting of CCR8 expression occurs early during T cell
activation
We previously reported that human epidermal keratinocytes release
soluble factors that synergize with TCR-activating signals to induce
CCR8 expression by naive T cells (12), but the kinetics of their
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action is not known. First, we determined at which time point
CCR8 expression was induced by analyzing RNA and protein
expression in activated naive T cells treated with ECM. We found
that CCR8 mRNA and protein expression began to rise after 3 d of
culture (Fig. 1A, 1B) coinciding with entry into cell division (data
not shown). CCR8 was not detected on undivided T cells, irre-
spective of the length of culture but reached peak expression by
day 4–5 on T cells that had undergone the most cell divisions
(Fig. 1C).
To determine when the CCR8-inducing factors were most active
in relation to TCR triggering, ECM was added either simulta-
neously with anti-CD3/CD28 beads (day 0) or on days 1, 2, or 3
following treatment with anti-CD3/CD28 beads (Fig. 1D). We
found that these factors are most potent when combined with TCR
triggering and that sensitivity to the skin-derived factors is lost as
the cells begin to divide (day 3). This suggests that the early
signaling events mediated by ECM factors and TCR stimuli im-
print a homing phenotype that only becomes apparent after 4–
5 d in culture (Fig. 1B, 1C); reminiscent of the intricate link be-
tween cell proliferation and differentiation as a result of epigenetic
alterations (15). Remarkably, even pulsing naive T cells with ECM
(i.e., 18-h culture followed by a washing step) prior to TCR
triggering resulted in significant CCR8 induction, indicating that
the active factor(s) could “imprint” resting T cells for skin homing
(Fig. 1E). Therefore, for the effective imprinting of a skin-homing
phenotype, exposure of T cells to the CCR8-inducing factor(s)
needs to occur either before or during T cell priming. As reported
previously, the addition of ECM to naive T cells did not affect
their survival (Supplemental Fig. 1A) or proliferation during
short-term culture (Supplemental Fig. 1B).
Intracellular cAMP is an important regulator of CCR8
expression
We next sought to identify the soluble factor(s) in ECM that are
responsible for this activity. Interestingly, the ability to induce
CCR8 expression was maintained in ECM or KCM cultures that
had been heat treated (80˚C) or digested with either proteinase K
or trypsin (Fig. 2A, 2B), whereas the enzymatic activity of HRP
was abolished under these conditions (data not shown). This
indicates that proteins and larger peptides are not responsible for
inducing CCR8 expression and implicated lipids and other small
molecules as primary candidates.
Because many lipids and small molecules act via G protein–
coupled receptors (GPCRs), we next tested whether ECM induced
the activation of second messengers commonly associated with
GPCR-mediated signaling. Incubating naive T cells with ECM for
30 min resulted in a transient 2.5-fold increase of intracellular
cAMP levels over media alone (Fig. 3A), suggesting that cAMP-
mediated signaling events may be involved in the regulation of
CCR8 expression. To test this further, naive T cells were stimu-
lated in the presence of the adenylate cyclase agonist forskolin and
found a dose-dependent upregulation of CCR8 expression that
peaked at 25 mM (Fig. 3B, 3C), indicating that cAMP is an es-
sential regulator of CCR8 expression. Similar to ECM, forskolin
induced a higher percentage of CD4+ T cells to express CCR8
than CD8+ T cells (Fig. 3C), suggesting that the mechanisms
regulating CCR8 expression differ between these two T cell
subsets. Importantly, TCR triggering itself induces an elevation
in cAMP levels (16) but fails to induce CCR8 expression, sug-
gesting that the effects of ECM and forskolin on cAMP levels are
qualitatively/quantitatively different from those derived from the
TCR.
We next tested GPCR agonists that are known to activate GaS
and found that the addition of PGE2, but neither the A2 adenosine
receptor agonist CV1808 nor the b2 adrenergic receptor agonist
isoproterenol, resulted in increased CCR8 expression by activated
T cells (Fig. 4A). PGE2 exerts its activity through four GPCRs
(EP1–4) with EP2 and EP4 being the most highly expressed by
naive T cells (17). By incubating naive T cells with EP-specific
antagonists, we found that the EP4 receptor–selective antagonist
L161,982 inhibited PGE2-induced CCR8 expression more con-
sistently and potently than either SC19220 (EP1) or AH6809
(EP1–3) (Fig. 4B), suggesting that EP4 was primarily responsible
FIGURE 1. CCR8 expression is imprinted early in activated T cells by
skin-derived factors. Naive T cells were stimulated with anti-CD3/CD28
beads in the presence of 15% ECM, and CCR8 expression was determined
examined on each day at the RNA level by quantitative PCR (A) and at the
protein level by flow cytometry (B). (C) T cell proliferation was monitored
in these cultures by CFSE dilution. Representative dot plots of CCR8
expression on CFSE-labeled CD4+ and CD8+ naive T cells stimulated for
4 d in the presence of ECM are shown. The percentage of proliferating
CD4+ and CD8+ cells expressing CCR8 for each cell division on day 4 is
plotted as mean 6 SD from three experiments. (D) Percentage of activated
T cells expressing CCR8 after 5 d in culture when ECM is added either
together with anti-CD3/CD28 beads (day 0) or on days 1, 2, or 3 post-
stimulation. (E) Naive T cells were pretreated with ECM for 18 h then
washed prior to stimulation with aCD3/CD28 beads. The percentage of
T cells expressing CCR8 was assessed after 5 d in culture. Results are
plotted as mean 6 SD from two to four independent experiments. *p ,
0.05, **p , 0.01.
FIGURE 2. CCR8 induction is mediated by conserved, nonproteina-
ceous factors. Naive T cells were stimulated for 5 d with anti-CD3/CD28
beads in the presence of ECM or KCM that had been heated to 80˚C or
digested with trypsin or proteinase K and analyzed for CCR8 expression
by flow cytometry after 5 d in culture. (A) Representative dot plots are
shown for gated CD4+ T cells, whereas in (B) the CCR8-inducing activity
of treated ECM/KCM relative to untreated for CD3+ T cells is plotted as
mean 6 SD from five independent experiments.
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for regulating CCR8 expression. In support, only the EP4-specific
agonist CAY10598 was capable of mimicking the PGE2 effect,
whereas the EP1/EP3 agonist 19R(OH)-PGE1 and the EP2 agonist
butaprost failed to do so (Fig. 4C).
Although both EP2 and EP4 activate cAMP signaling, EP4 has
also been shown to activate the PI3K signaling pathway (18). As
such, we next tested which pathway was primarily responsible for
inducing CCR8 expression by preincubating cells with increasing
concentrations of either the PKA-selective inhibitory peptide PKI,
the PI3K inhibitor wortmannin, or the Raf1 inhibitor Raf1 kinase
inhibitor 1 prior to the addition of PGE2. For this experiment, the
pulsing of naive T cells with PGE2 with or without the signaling
inhibitors prior to the addition of anti-CD3/CD28 beads was
necessary to prevent the signaling inhibitors from interfering with
T cell activation. In accordance with our forskolin data (Fig. 3),
we found that only incubation with PKI significantly reduced
PGE2-induced CCR8 expression on activated T cells (Fig. 4D,
4E).
The downstream effects of cAMP are thought to be mediated by
the various isoforms of PKA (19). Therefore, we tested whether
there was a preference for PKA type I or type II in the regulation
of CCR8 expression by comparing the effect of PKA subtype–
specific cAMP analogs (20). Interestingly, whereas the preferential
activation of either PKA-I or PKA-II failed to induce significant
CCR8 expression, combining these analogs resulted in a strong
synergy indicating that the activation of both isoforms is essential
FIGURE 3. Intracellular cAMP is an important regulator of CCR8 expression. (A) Fold increase in intracellular cAMP levels for naive T cells cultured
with 15% ECM for 30 min at 37˚C compared with media alone from two independent experiments using ECM preps from six healthy skin donors. (B)
Representative dot plots for CCR8 expression by gated CD4+ T cells activated for 5 d in the absence (media) or presence of 10 mM forskolin. (C) Per-
centage of gated CD4+ and CD8+ T cells expressing CCR8 after 5 d in culture following stimulation with anti-CD3/CD28 beads in the presence of in-
creasing concentrations of forskolin, plotted as mean 6 SD from three independent experiments. *p , 0.05, **p , 0.01.
FIGURE 4. PGE2 mediated activation of PKA results in CCR8 expression. (A) Naive T cells were stimulated for 5 d with anti-CD3/CD28 beads in the
presence of 0.01–10 mM PGE2, isoproterenol or CV1808. The percentage of gated CD3
+ T cells expressing CCR8 was determined by flow cytometry and
plotted as mean6 SD from two to six independent experiments. (B) Naive T cells were incubated with PGE2 alone or PGE2 in the presence of 0.01–10 mM
of antagonists against EP1 (SC19220), EP1/2 (AH6809), or EP4 (L161,982) prior to stimulation with anti-CD3/CD28 beads. After 5 d, the percentage of
cells expressing CCR8 was determined by flow cytometry and plotted as a percentage of cells expressing CCR8 relative to PGE2 alone. Results are plotted
from two independent experiments. (C) Naive T cells were stimulated in the presence of 0.01–1 mM PGE2 or the EP-selective agonists 19R(OH)-PGE1
(EP1), butaprost (EP2), or CAY10598 (EP4). After 5 d, the percentage of CD3+ T cells expressing CCR8 was determined by flow cytometry, and results are
plotted as mean6 SD from four independent experiments. (D and E) Naive T cells were pretreated with 0.01–1 mM of the inhibitors Raf1 kinase inhibitor 1
(RKI1), wortmannin, or PKA inhibitor peptide PKI14–22 (PKI) prior to stimulation in the presence of PGE2. Representative dot plots for CCR8 expression
by gated CD3+ T cells stimulated in the presence of PGE2 alone or PGE2 + 1 mM PKI are shown in (D), whereas bar graphs depicting the percentage of
CD3+ T cells expressing CCR8 for inhibitor-treated groups relative to PGE2 alone are plotted in (E). (F) Naive T cells were stimulated for 5 d in the
presence of 0.1 mM of site-specific cAMP agonists selective for activation of PKA-I (2-Cl-8-MA-cAMP + 8-Pip-cAMP) and PKA-II (N6-MBC-cAMP +
8-Pip-cAMP) (20). The percentage of CD3+ T cells expressing CCR8 was determined by flow cytometry after 5 d and plotted as mean 6 SD from two
independent experiments. *p , 0.05, **p , 0.01.
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for CCR8 expression (Fig. 4F). This finding clarifies why neither
TCR triggering alone nor activation of the b2 adrenergic receptor
are effective at inducing CCR8 expression as these receptors pref-
erentially activate PKA-I (21, 22). We conclude that the cAMP
elevating agents PGE2 and forskolin are potent CCR8-inducing
agents when added at micromolar concentrations.
Active vitamin D3 synergizes with PGE2 to induce CCR8
expression
PGE2 alone is not as effective as ECM at inducing CCR8 ex-
pression, and PGE2 levels in ECM are below micromole con-
centrations (44.8 6 33.9 nM; 14.95–83.72 nM; n = 5), suggesting
that other factor(s) may work in concert with PGE2. Previous
reports highlight the critical role for vitamins A and D in the
regulation of tissue-homing receptor expression (3). However,
neither of these vitamins alone showed significant activity in our
previous human CCR8 induction experiments. To our surprise, we
found that the combination of 1,25(OH)2D3, a metabolite typically
found in ECM cultures, with suboptimal levels (0.1 mM) of PGE2
resulted in a significant increase in the percentage of CD4+ and
CD8+ T cells expressing CCR8 over PGE2 alone (p , 0.0001) or
1,25(OH)2D3 alone (p , 0.01; Fig. 5A, 5B). Interestingly, com-
bining these metabolites resulted in a synergistic increase in
CCR8 expression for five of the nine responding T cell donors
tested, whereas the remaining four donors only showed an additive
response (Fig. 5C). The reason for this difference is unclear but
may reflect donor variability in the responsiveness to these
metabolites as well as the timing of delivery. However, it is im-
portant to note that for some donors the response to 1,25(OH)2D3
alone was relatively high when compared with the median
(Fig. 5B) or when compared with previously published experi-
ments (12). For these donors, it is conceivable that the effect of
1,25(OH)2D3 alone precluded any synergistic effect when com-
bined with PGE2. Of note, and in line with our findings with ECM,
CCR8 expression in CD4+ T cells routinely exceeded the levels
observed in CD8+ T cells (data not shown). This effect was spe-
cific for the active metabolite of vitamin D3 because neither the
precursor 25(OH)D3 nor the vitamin A metabolite, all-trans-retinoic
acid, showed synergistic activity (Fig. 5A; data not shown). This
synergistic effect could also be seen when 1,25(OH)2D3 was
combined with suboptimal levels of the EP4 receptor agonist
CAY10598 (Fig. 5D) as well as forskolin (data not shown) but not
the EP1/EP3 agonist 19R(OH)-PGE1 or the EP2 agonist butaprost
(Fig. 5D).
We previously reported that the addition of IL-12 to T cell–
keratinocyte cocultures inhibited the keratinocyte-mediated CCR8
induction (12). In agreement, in this paper, we report that the
addition of IL-12 inhibited the synergy between 1,25(OH)2D3 and
0.1 mM PGE2 during induction of CCR8 expression (Fig. 5E),
which is in contrast to CCR10, whose modest expression depen-
ded on this cytokine (Fig. 5F). Likewise, the addition of IFN-a also
significantly reduced the percentage of activated T cells expressing
CCR8 after treatment with PGE2 plus 1,25(OH)2D3, whereas IFN-g,
IL-6, and TNF-a did not have this effect. The inhibitory effect of
IL-12 and IFN-a could be seen for both CD4+ and CD8+ T cells
(Supplemental Fig. 2A), and similar data were obtained when using
only 50 nM PGE2 in combination with 1,25(OH)2D3 (Supplemental
Fig. 2B) or when T cells were stimulated in the presence of ECM
(Supplemental Fig. 2C).
Because ECM possessed the ability to “imprint” a skin-homing
phenotype in responding T cells (Fig. 1E), we next examined
whether 1,25(OH)2D3 could prime naive T cells for CCR8 ex-
FIGURE 5. Ability of 1,25(OH)2D3 to enhance PGE2-mediated CCR8 induction. (A–C) Naive T cells were stimulated in the presence of 0.1 mM PGE2
alone, 0.1 mM 1,25(OH)2D3 alone, or PGE2 in combination with either 0.1 mM 1,25(OH)2D3 or 0.1 mM 25(OH)D3. (A) Representative dot plots for CCR8
expression on gated CD4+ and CD8+ T cells after 5 d are shown, whereas in (B) the percentage of gated CD3+ T cells, expressing CCR8 is plotted for each
responding donor (n = 9). Line (—) denotes geometric mean. (C) The response of each donor to these treatments is plotted according to whether the
resulting percentage of CCR8 expressing T cells in response to PGE2 + 1,25(OH)2D3 exceeded the sum of either metabolite alone (synergy; left panel) or
whether it was equal to the sum of the responses induced by each metabolite alone (additive; right panel). (D) Naive T cells were stimulated in the presence
of various EP receptor agonists at 0.01 or 0.1 mM in media alone or in combination with 0.1 mM 1,25(OH)2D3. The percentage of CD4
+ T cells expressing
CCR8 was determined after 5 d and plotted as mean 6 SD from two independent experiments. (E and F) Naive T cells were stimulated in the presence of
0.1 mM PGE2 + 0.1 mM 1,25(OH)2D3 in the absence or presence of 12.5 ng/ml IL-12, 100 U/ml IFN-a, 12.5 ng/ml IFN-g, 50 ng/ml IL-6, or 20 ng/ml TNF-a.
After 5 d, the percentage of CD3+ T cells expressing CCR8 (E) or CCR10 (F) was determined by flow cytometry. The percentage of cells expressing CCR8
is plotted in (E) as mean 6 SD relative to T cells treated with PGE2 + 0.1 mM 1,25(OH)2D3 alone from five independent experiments. *p , 0.05, **p ,
0.01, ***p , 0.001, ****p , 0.0001.
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pression. To do so, naive T cells were first pulsed with either
1,25(OH)2D3 alone, 1,25(OH)2D3 plus IL-12, or its precursor
25(OH)D3 for 18hrs, washed and then stimulated with anti-
CD3/CD28 beads in the presence of a suboptimal concentrations
of PGE2 (0.025–0.1 mM). Consistent with our findings with ECM,
the pulsing of T cells with 1,25(OH)2D3, but not its inactive pre-
cursor, 25(OH)D3, resulted in a significant increase in CCR8 ex-
pression over either PGE2 alone (p , 0.001 for 0.025 mM PGE2)
or 1,25(OH)2D3 alone (p , 0.001; Fig. 6A, 6B), indicating that
skin-derived 1,25(OH)2D3 does not need to be present at the time
of activation and plays an important role in conditioning T cells
for skin homing. Interestingly, and in contrast to data shown in
Fig. 5C, pulsing naive T cells with 1,25(OH)2D3 prior to activa-
tion in the presence of PGE2 resulted in a synergistic response for
all donors tested (Fig. 6C), whereas pulsing with 1,25(OH)2D3 in
the presence of IL-12 inhibited this synergy, revealing an early
inhibitory effect of IL-12. These findings are in line with the view
that the active metabolite of vitamin D3 acts on local T cells before
they interact with local DCs or migratory DCs in the draining
lymph nodes following their exit from the skin.
Regulation of CCR8 expression by skin tissue is conserved
between mice and humans
A recent study suggested that CCR8 expression is also restricted to
skin tissue in mice (23). As a result, we next examined tissues from
healthy B6 mice and found that CCR8 mRNA expression is
largely restricted to the CD45+ fraction of immune cells localized
in the skin and skin-draining lymph nodes, and consistent with
a previous report, CCR8 mRNA was also detected at high levels
in murine thymocytes (Fig. 7A) (24, 25). Further examination us-
ing custom-made AF647-labeled murine CCL1 (AF647-muCCL1)
determined that, as in humans, CCR8 is primarily expressed by
memory (CD44hi) T cells present in the skin and skin-draining
lymph nodes (Fig. 7B) as well as by some single-positive and
double-negative thymocytes (Supplemental Fig. 3). In murine
skin, expression was detected on both CD4+ and CD8+ skin
T cells, whereas expression in draining lymph nodes was re-
stricted to the CD4+ subset, consistent with previous reports
showing that the recirculation patterns of the two memory T cell
subsets differ (26–28). In contrast, significant levels of CCR8 were
not detected on lymphocytes isolated from the spleen, mesenteric
lymph nodes, or even peripheral blood (Fig. 7B, Supplemental
Fig. 3).
On the basis of the comparatively conserved expression patterns
of CCR8, we next asked whether the mechanism regulating human
CCR8 expression would also regulate murine CCR8 expression.
Activation of naive mouse T cells in the presence of mouse skin–
conditioned medium resulted in the upregulation of murine CCR8
mRNA (Fig. 7C) and surface protein expression (Fig. 7D) signi-
fying a conserved cross-species regulation of CCR8 expression by
skin tissue. As for induction of human CCR8, this effect was more
prominent on murine CD4+ than CD8+ T cells and could be
replicated using ECM prepared from dorsal epidermal sheets (data
not shown). However, unlike human T cells, the elevation of in-
tracellular cAMP was not required for murine CCR8 expression as
neither forskolin (Fig. 7E) nor cAMP analogs (data not shown)
were capable of inducing CCR8 expression at the mRNA (Fig.
7E) or protein level (data not shown) in activated mouse T cells.
In agreement, the addition of either PGE2 alone or PGE2 plus
1,25(OH)2D3 were also ineffective in inducing CCR8 expression
(Fig. 7F). Inactivity of these factors may reflect differences in
human and mouse T cell responsiveness to 1,25(OH)2D3 as was
reported in the regulation of CCR10 expression (10). Of note,
vitamin D synthesis is absent in murine skin (29), explaining why
this metabolite cannot participate in immune modulatory pro-
cesses in the skin of mice and possibly other nocturnal verte-
FIGURE 6. 1,25(OH)2D3 primes PGE2-mediated
CCR8 induction. Naive T cells were left untreated or
pulsed with either 1,25(OH)2D3 alone, 1,25(OH)2D3 +
IL-12, or 25(OH)D3 for 18 h, washed, and then stim-
ulated with anti-CD3/CD28 beads in the absence
or presence of suboptimal concentrations of PGE2
(0.025, 0.05, or 0.1 mM). (A) Representative dot plots
for CCR8 expression on gated CD3+ T cells 5 d
poststimulation for T cells pretreated overnight
with media, 1,25(OH)2D3 alone, or 1,25(OH)2D3 +
IL-12, followed by stimulation in the absence (media)
or presence of 0.025 mM PGE2 are shown. (B) The
percentage of CD3+ T cells expressing CCR8 after
5 d for all treatment groups is plotted as mean 6 SD
from three to six independent experiments. (C) The
percentage of CD3+ T cells expressing CCR8 for
T cells stimulated in the presence of 0.1 mM PGE2
(i.e., pulsed with media alone), T cells pulsed with
1,25(OH)2D3 alone, followed by stimulation in the
absence of PGE2 or T cells pulsed with 1,25(OH)2D3,
followed by stimulation in the presence of PGE2 is
plotted for each donor (n = 6). The effect on CCR8
expression of pulsing T cells with 1,25(OH)2D3, fol-
lowed by stimulation in the presence of PGE2 ex-
ceeds the sum of the effects of either metabolite
alone. *p, 0.05, **p, 0.01, ***p, 0.001, ****p,
0.0001.
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brates. However, the possibility that other factors combine with
1,25(OH)2D3 in the regulation of mouse CCR8 cannot be ex-
cluded. Nevertheless, it is clear that CCR8-expressing memory
T cells accumulate in the skin of mice and humans and that skin
tissue-derived factors regulate CCR8 expression in both species
and, as such, underlies a conserved mechanism in the localiza-
tion of skin-specific memory T cells.
Discussion
Control of tissue-resident memory T cells by distinct tissue
environments represents a new paradigm in peripheral immune
surveillance. The importance of this paradigm is underscored by
the fact that healthy peripheral tissues harbor vast numbers of
memory T cells whose presence is essential for maintaining tissue
integrity and longevity. In this study, we show a mechanism for the
control of human CCR8 expression involving the skin-produced
metabolites 1,25-dihydroxyvitamin D3 and PG E2. Activation of
the cAMP/PKA-signaling pathway was found to be essential for
the induction of CCR8, and in agreement, PGE2 alone could in-
duce CCR8 expression. However, this effect was only observed at
high (micromolar) concentrations of PGE2, whereas induction of
CCR8 at concentrations of PGE2 produced by steady-state epi-
dermis only occurred in the presence of the active vitamin D
metabolite, 1,25(OH)2D3. Our data highlight an important role
for vitamin D3 in modulating the expression of skin-homing che-
mokine receptors in a context-driven manner. In the presence of
the inflammatory cytokines IL-12 (10) or TNF-a plus IL-6 (30),
1,25(OH)2D3, induces low-level expression of the chemokine re-
ceptor CCR10 in T cells, whereas in the presence of basal levels of
PGE2, we found that 1,25(OH)2D3 synergistically enhanced ex-
pression of CCR8. Importantly, we also found that the addition of
the type 1 proinflammatory cytokines IL-12 and IFN-a inhibited
CCR8 expression, suggesting that CCR8 and CCR10 are induced
under different circumstances, although further investigation is
needed. In support, we have reported that CCR8 is expressed by a
majority of memory T cells isolated from healthy human skin,
whereas CCR10 is largely absent (12).
Skin is the primary site for vitamin D3 synthesis because its
precursor 7-dehydrocholesterol (or provitamin D) is uniquely
produced at high levels in this tissue (31). Upon exposure to
sunlight, this precursor is converted to previtamin D3, which then
isomerizes spontaneously over time to vitamin D3. This conver-
sion occurs almost exclusively within the epidermis because UVB
penetration is limited to this layer (31). Although the majority of
vitamin D3 is then transported to the liver and kidney for con-
version to 25(OH)D3 and its active form 1,25(OH)2D3, respec-
tively, basal keratinocytes also express the necessary enzymes
(25-hydroxylases and 1-hydroxylase) to convert vitamin D3 to
1,25(OH)2D3, indicating that skin tissue itself is a source of the ac-
tive metabolite (32). Local production is essential as 1,25(OH)2D3
is required for keratinocyte differentiation (33) and skin tissue
defense (34), but the levels found in circulation are low (,100 pM)
and are unlikely to sufficiently supply the epidermis. Interestingly,
the photosynthesis of vitamin D appears to be an adaptation of
diurnal vertebrates to sunlight because nocturnal animals, includ-
ing rodents, do not possess this ability (29, 35). This provides an ex-
planation for why certain skin tissue–expressed immune-associated
genes such as cathelicidin (36), CCR10 (10, 37), and CCR8, as
shown in this study, are positively regulated by 1,25(OH)2D3 in
humans but not in mice.
Vitamin D3 plays an important immune-modulatory role be-
cause deficiency in this vitamin in humans is associated with in-
creased incidence of infection and autoimmunity (38). In terms of
T cell differentiation, 1,25(OH)2D3 is thought to play a predomi-
nant inhibitory role because it indirectly promotes the differenti-
ation of regulatory T cell subsets through its actions on dendritic
FIGURE 7. Conserved regulation of murine CCR8 expression by skin tissue. (A and B) Expression of murine CCR8 was evaluated by quantitative PCR
in purified CD45+ and CD45neg cell populations isolated from the skin, spleen, skin-draining lymph nodes, and thymus (A) and by flow cytometry on gated
CD8+ and CD4+ memory (CD44hi) T cells isolated from mouse skin, skin-draining LN (dLN), mesenteric LN (mLN), and spleen (B) from wild-type B6
mice stained with AF647-muCCL1. Data in (A) are plotted relative to the skin CD45-negative population. (C and D) Naive splenic T cells were stimulated
in vitro with plate-bound anti-CD3 plus soluble anti-CD28 in the absence or presence of mouse skin–conditioned medium (SCM). After 5 d, cells were
harvested and assayed for CCR8 expression at the RNA level by quantitative PCR (C) or stained with AF647-muCCL16 excess unlabeled muCCL1 (D) to
detect surface CCR8 expression by flow cytometry on gated CD4+ T cells. Results in (C) are plotted as mean 6 SD from two independent experiments (n =
2–3 mice) and dot plots in (D) are representative of four independent experiments from cells pooled from two to three mice each. (E) Naive splenic T cells
were stimulated in vitro with plate-bound anti-CD3 plus soluble anti-CD28 in the absence or presence of 10 or 25 mM forskolin. After 5 d, cells were
harvested and assayed for CCR8 expression at the RNA level by quantitative PCR. (F) Naive splenic T cells were stimulated in vitro with plate-bound anti-
CD3 plus soluble anti-CD28 in the presence of 1 mM PGE2, 0.1 mM 1,25(OH)2D3 alone, or PGE2 + 1,25(OH)2D3. After 5 d, cells analyzed for CCR8
expression by flow cytometry. nd, not detected.
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cells (DCs) (39, 40), whereas it primarily inhibits the differentia-
tion of other Th cell subsets (41). Whether the effects of 1,25(OH)2D3
on T cell differentiation are due solely to indirect actions via DCs
is unclear, but our findings along with those from Sigmundsdottir
et al. (10) clearly show that 1,25(OH)2D3 acts directly on human
T cells to promote skin homing receptor expression. On the basis
of these data, it is possible that the decreased production of vita-
min D3 in aged skin could be a factor in the age-related decline in
the local skin immune memory response (42, 43).
PGE2 has also been previously implicated in the regulation of
skin immune cell migration. Specifically, PGE2 was shown to
promote the maturation and migration of Langerhans cells, and as
in our study, this effect was dependent on signaling through EP4
(44). More recently, PGE2 was shown to indirectly promote a skin-
homing phenotype in responding T cells as a result of its action on
DCs. A study by Stock et al. (45) demonstrated that skin-produced
PGE2 was responsible for inhibiting the expression of retinoic
acid–producing enzymes by DCs. As a consequence, T cells
primed with these “skin-conditioned” DCs had higher expres-
sion of P-selectin ligands and accumulated in murine skin tissue
(45). However, it remains unclear as to how interference with
vitamin A metabolism in DCs promotes skin tropism in activated
T cells. In human T cells, retinoid acid, the active form of vitamin
A, did not interfere with CCR8 expression (12).
Like vitamin D3, PGs are also important for skin tissue ho-
meostasis (46). In fact, PGE2 is one of the main cutaneous eico-
sanoids produced by both epidermal keratinocytes and dermal
fibroblasts. However, only primary cultures of epidermal kerati-
nocytes are capable of producing both PGE2 and 1,25(OH)2D3,
consistent with their unique ability to support CCR8 expression
(12). Many of the effects of PGE2 on immune cells have been
attributed to the activation and accumulation of intracellular
cAMP and its downstream activation of cAMP-dependent PKA. In
agreement, in this paper, we document that the PGE2-mediated
induction of CCR8 expression in naive T cells required PKA
signaling. Although inhibitory at high levels (47, 48), the gener-
ation of intracellular cAMP has also been shown to be necessary
in the differentiation of Th1 and Th17 cells (49) and also to
promote the responsiveness of primed T cells to restimulation
(50).
Our study emphasizes the unique role played by tissues in
maintaining the tissue-specific immune surveillance T cell reper-
toire. We propose that the skin tissue environment provides signal 3
in the multistep process of immune memory T cell formation. TCR
triggering during adhesive interaction of naive T cells with Ag-
presenting DCs provides signal 1 and leads to primed T cells
receptive for costimulatory signals (signal 2) that drive T cell
differentiation and expansion. Epidermis-derived factors, includ-
ing 1,25(OH)2D3 and PGE2, as shown in this study, play an am-
bassador role in relaying the tissue-homing information (signal 3)
to local, emigrating, and/or skin-draining lymph node T cells.
Because CCR8+ T cells predominate in healthy skin, we suggest
that signal 3 is primarily active during the steady state (i.e., under
conditions of immune homeostasis). This suggests that signal 3
could occur prior to T cell activation (signal 1 and 2), consistent
with our priming data. Under inflammatory conditions, the effect
of skin factors may be overridden by inflammatory mediators
(i.e., IL-12 and IFN-a) that ensure the recruitment of newly
generated effector T cells in response to inflammatory chemo-
kines. We do not yet know how CCR8+ T cells relate to inflam-
matory T cells and, indeed, when during the course of primary
immune responses CCR8+ T cells are being formed. We have
noted that excessive TCR triggering (i.e., high anti-CD3 concen-
trations neutralized the effect of CCR8-inducing factors [unpub-
lished observations]), which agrees with the view that CCR8
becomes expressed during the resolution phase of inflammation
when the Ag density on DCs becomes limited. A recent study
examining the differentiation of skin-resident memory T cells in
mice found that CCR8 mRNA levels increased in tissue-resident
T cells during the resolution phase of an immune response
(.7 d postchallenge) (23). It remains to be investigated whether
CCR8 expression occurs locally (i.e., at the late stage of inflam-
mation) or in tissue-specific lymph nodes that drain the necessary
signal 3 tissue factors. Even though the CCR8-inducing factors
appear to differ between mice and humans, our findings show that
the localization of CCR8+ memory T cells and the regulation of
CCR8 expression by skin tissue are conserved, indicating that it is
now possible to investigate the kinetics of CCR8 expression in
mouse models of skin infections and vaccination.
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